Abstract:Abstract Apart from EGFR T790M mutation, the bypass activation of c-Met and Axl kinase also can lead to the resistance to tyrosine kinase inhibitors (TKIs) in NSCLC. Axl and c-Met share same downstream pathways with EGFR, thus combined treatments of EGFR inhibitors with Axl or Met inhibitor are promising to overcome acquired resistance of TKIs. Our previous work showed that the water extract of Marsdenia tenacissima (MTE), which used to treat cancer in clinics for decades, restored gefitinib sensitivity in resistant NSCLC cells with EGFR T790M mutation or K-ras mutations in vitro and in vivo. However, the potential effeicacy of MTE on Axl and c-Met mediated resistance has not yet been fully understood, and the related molecular mechanisms also need to be elucidated. The present study was performed on HCC827/ER cells, which was established by exposing parental HCC827 cells to erlotinib. HCC827/ER cells are with Axl activiation and c-Met amplification, and show dual-resistance to erlotinib and gefitinib. We evaluated the effects of MTE to restore erlotinib/gefitinib sensitivity with three different combinations. Cell viability and cell apoptosis were determined by MTT and flow cytometry, respectively. The c-Met amplification was assessed with TaqMan real-time PCR. Signaling pathways were examined by Western blotting to reveal the possible mechanisms. The in vivo effects of MTE combined with erlotinib/gefitinib were tested on HCC827/ER xenograft mice, and tumor tissues were subjected to immunohistochemistry analysis and Western blotting. Our results indicated the MTE→MTE+Erlotinib/Geftinib (M→M+E/G) treatment was the most potent combinations. Compared with control group and each single, M→M+E/G treatment induced significant apoptosis, obviously inhibited EGF-induced phosphorylation of PI3K/Akt/mTOR and ERK1/2, down-regulated HGF/c-Met activation in HCC827/ER cells. Axl is a receptor tyrosine kinase which strongly associated with EMT phenotype. The M→M+E/G treatments could not restrain Axl expressions but remarkably reduced phospho-Axl levels and inhibited EMT phenotype in HCC827/ER cells. Surprisingly, MTE alone caused prominent p-Axl inhibition, along with up-regulated E-cadherin and decreased mesenchymal markers. The mouse tumors were remarkably restrained by the M→M+E/G combinations, and it was significant compared with each drug alone (P<0.05). Accordingly, cell apoptosis was extended, PCNA expression and tumor angiogenesis (VEGF and CD105) were reduced and EMT phenotype were regulated in tumor tissues. The p-Met and p-AXL were also considerably suppressed by the combined treatments. The present data revealed that MTE restored TKIs such as erlotinib and gefitinib efficacy in resistant NSCLC cells with Axl activation and c-Met amplification in vitro and in vivo. It suggests that the addition of MTE may be a promising therapeutic strategy to overcome TKIs resistance in NSCLC. Citation Format: Shu-Yan Han, Hong Sun, Dong Xue, Wei Zhao, Yan-Na Jiao, Ping-Ping Li. Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by Marsdenia tenacissima extract [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1199. doi:10.1158/1538-7445.AM2017-1199

Methylseleninic Acid Overcomes Gefitinib Resistance Through Asparagine-Met-topk Signaling Axis in Non-Small Cell Lung Cancer Cells.

Arsenic Circumvents the Gefitinib Resistance by Binding to P62 and Mediating Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer

The Mechanism of Gefitinib Resistance Induced by Hepatocyte Growth Factor in Sensitive Non-small Cell Lung Cancer Cells in Vitro

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Targeting a Novel COX2/MET/TOPK Signaling Axis Overcomes Gefitinib Resistance in NSCLC

Marsdenia Tenacissima Extract Overcomes Axl- and Met-mediated Erlotinib and Gefitinib Cross-Resistance in Non-Small Cell Lung Cancer Cells

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration

Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC

Abstract 1199: Overcomes AXL and Met mediated erlotinib/gefitinib cross resistance in non-small cell lung cancer cells by<i>Marsdenia tenacissima</i>extract

Marsdenia Tenacissima Extract Restored Gefitinib Sensitivity in Resistant Non-Small Cell Lung Cancer Cells.

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Increased Glutamine Anabolism Sensitizes Non-Small Cell Lung Cancer to Gefitinib Treatment.

Abstract 1199: Overcomes AXL and Met Mediated Erlotinib/gefitinib Cross Resistance in Non-Small Cell Lung Cancer Cells Bymarsdenia Tenacissimaextract

Methylseleninic Acid Overcomes Programmed Death-Ligand 1-Mediated Resistance of Prostate Cancer and Lung Cancer.

P3.02b-123 Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells

Marsdenia Tenacissima Extract Enhances Gefitinib Efficacy in Non-Small-Cell Lung Cancer Xenografts

Mechanism of SU11274 Reversing the Resistance to Erlotinib Induced by Hepatocyte Growth Factor in Non-small Cell Lung Cancer Cells

SFI Enhances Therapeutic Efficiency of Gefitinib: an Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells